US 11,813,458 B2
Methods and systems for target localization and DBS therapy
Rosana Esteller, Santa Clarita, CA (US); Mahsa Malekmohammadi, Sherman Oaks, CA (US); Andrew Haddock, Los Angeles, CA (US); and Tianhe Zhang, Studio City, CA (US)
Assigned to Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed by Boston Scientific Neuromodulation Corporation, Valencia, CA (US)
Filed on Mar. 7, 2022, as Appl. No. 17/653,814.
Claims priority of provisional application 63/263,634, filed on Nov. 5, 2021.
Claims priority of provisional application 63/162,887, filed on Mar. 18, 2021.
Prior Publication US 2022/0296892 A1, Sep. 22, 2022
Int. Cl. A61N 1/05 (2006.01); A61N 1/36 (2006.01)
CPC A61N 1/3614 (2017.08) [A61N 1/0534 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of determining a cause of a decline in therapeutic efficacy of deep brain stimulation (DBS) in a patient having an electrode lead implanted in their brain, the electrode lead comprising a plurality of electrodes, the method comprising:
providing stimulation to the patient's brain using a first one or more of the plurality of electrodes implanted in the patient's brain, wherein the stimulation is configured to provide therapy to the patient,
receiving an indication of a decline in therapeutic efficacy of the stimulation,
determining impedances at one or more of the plurality of electrodes,
sensing evoked potentials evoked by the stimulation using one or more of the plurality of electrodes, and
determining a cause of the decline in therapeutic efficacy based on both the impedances and the evoked potentials.